# CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial

Source: [BioPharma Dive - Latest News](https://www.biopharmadive.com/news/cg-oncology-cretostimogene-adjuvant-bladder-cancer-results-pivot/874740/) · 2026-11-16 · Medicine
Page: https://themorning.science/story/cg-oncology-drug-delivers-exceptional-results-in-key-bladder-cancer-trial-8614a8515455edc1
Kind: research · Impact: medium

## In brief

- CG Oncology reported that its therapy cretostimogene cut the risk of recurrence by 68% when given after surgery in a key bladder cancer trial.
- The results were reported as far exceeding Wall Street's expectations and lifted the company's shares.
- The source describes the results as 'exceptional'.

## Why it matters

The trial reports a large reduction in bladder cancer recurrence after surgery, which could shape how adjuvant treatment is evaluated for this disease.

## Timeline

- 2026-11-16: BioPharma Dive reports CG Oncology's trial results showing a 68% reduction in recurrence risk

## Coverage

- [CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial](https://www.biopharmadive.com/news/cg-oncology-cretostimogene-adjuvant-bladder-cancer-results-pivot/874740/) — BioPharma Dive - Latest News, 2026-11-16

Tags: bladder cancer, oncology, clinical trial, cretostimogene, recurrence

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
